# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k050113   
B. Purpose for Submission: Addition of CSF as sample matrix to previously cleared Tina-Quant $^ \mathrm { \textregistered }$ IgG Gen.2 application for measurement in human serum and plasma.   
C. Measurand: IgG   
D. Type of Test: Immunoturbidimetric, Quantitative   
E. Applicant: Roche Diagnostics   
F. Proprietary and Established Names: Tina-Quant $^ \mathrm { \textregistered }$ IgG Gen.2

# G. Regulatory Information:

2. Classification: Class II

3. Product code: DEW IgG, Antigen, Antiserum, Control

4. Panel: Immunology (82)

# H. Intended Use:

1. Intended use(s): Immunoturbidimetric assay for the quantitative in vitro determination of IgG in human serum, plasma, and cerebrospinal fluid (CSF) on Roche automated clinical chemistry analyzers.   
2. Indication(s) for use: Measurement of IgG aids in the diagnosis of abnormal protein metabolism and the body's lack of ability to resist infectious agents.   
3. Special conditions for use statement(s): For prescription use only.   
4. Special instrument requirements: For Roche/Hitachi 904, 911, 912, 917, MODULAR P:

# I. Device Description:

Tina-Quant $^ \mathrm { \textregistered }$ IgG Gen.2 consists of the following:

R1 TRIS\* buffer: $2 0 \mathrm { m m o l / L }$ , pH 8.0; NaCl: 200 mmol/L; polyethylene glycol: $3 . 6 \%$ ; preservative and stabilizers.   
R2 Anti-human IgG antibody (goat): dependent on titer; TRIS\* buffer: $2 0 \mathrm { m m o l / L }$ , $\mathsf { p H 8 . 0 }$ ; NaCl: 150 mmol/L; preservative.   
${ } ^ { * } \mathrm { T R I S } = { } ^ { \prime }$ Tris(hydroxymethyl)-aminomethane

Calibrators for the standard application include Preciset Serum Proteins or C.f.a.s. Proteins; the calibrator for the sensitive application is C.f.a.s. PUC (Proteins in Urine/CSF). These were cleared as k040264. The recommended control materials for the standard application are Precinorm Protein and Precipath Protein; the recommended control materials for the sensitive application are Precinorm PUC (Proteins in Urine/CSF) and Precipath PUC. These were cleared as k041812. IgG analyte values were added to these calibrators and controls and were assigned k050026.

Calibrators and controls are sold separately.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Dade Behring N Antisera to Human Immunoglobulins (IgG, IgA, and IgM) IgG assay on the BN II   
2. Predicate 510(k) number(s): k943997   
3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Tina-Quant ® IgG Gen.2</td><td rowspan=1 colspan=1>Dade-Behring N Antiserato HumanImmunoglobulins IgG onBN II</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Immunoturbidimetric assayfor the quantitative in vitrodetermination of IgG inhuman serum, plasma, andcerebrospinal fluid (CSF)on Roche automatedclinical chemistryanalyzers.</td><td rowspan=1 colspan=1>In vitro diagnostic reagentsfor the quantitativedetermination ofimmunoglobulims (IgG,IgA, and IgM) in humanserum as well as of IgG inhuman urine andcerebrospinal fluid (CSF)</td></tr><tr><td rowspan=1 colspan=1>Traceability /Standardization</td><td rowspan=1 colspan=1>CRM 470</td><td rowspan=1 colspan=1>CRM 470</td></tr><tr><td rowspan=1 colspan=1>Sample Types</td><td rowspan=1 colspan=1>Serum, plasma, CSF</td><td rowspan=1 colspan=1>Serum, plasma, urine, CSF</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">Sensitive application (CSF):C.f.a.s. (Calibrator for</td><td colspan="1" rowspan="1">N Proteins Standard SL(human)</td></tr><tr><td colspan="1" rowspan="1">Y</td><td colspan="1" rowspan="1">automated systems) PUC</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">Roche/Hitachi family ofanalyzers</td><td colspan="1" rowspan="1">BN Systems</td></tr><tr><td colspan="1" rowspan="1">Expected values</td><td colspan="1" rowspan="1">10-30 mg/L</td><td colspan="1" rowspan="1">Below 34 mg/L</td></tr><tr><td colspan="1" rowspan="1">Analytical Sensitivity</td><td colspan="1" rowspan="1">2 mg/L</td><td colspan="1" rowspan="1">Established by lowerlimit of reference curve</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

None referenced.

# L. Test Principle:

The immunoturbidimetric methodology utilized in this assay is the basis for the already cleared TinaQuant IgG Gen.2 application for measurement in human serum and plasma. During the reaction, anti-IgG antibodies react with antigen in the sample to form an antigen-antibody complex. Following agglutination, the complex is measured turbidimetrically. PEG is added to the reaction to allow the reaction to progress rapidly to end point and improve sensitivity.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility:

Within-run precision: The within-run precision for the Sensitive (CSF) application was determined by 21replicate determinations of two controls and two human CSF samples on the Hitachi 917 analyzer.

<table><tr><td>Analyte: Instrument:</td><td>IgG</td></tr><tr><td>Hitachi 917</td><td></td></tr><tr><td>Reagent:</td><td>IGGC2 Lot E01</td></tr><tr><td>Calibrator:</td><td>CfaS-PUC Lot 15575299 c=227 mg/L autodilution</td></tr></table>

<table><tr><td rowspan=1 colspan=5>Reagent:       IGGC2 Lot E01Calibrator:    CfaS-PUC Lot 15575299 c227 mg/L autodilutionResults:        Control low   Control high</td></tr><tr><td rowspan=1 colspan=1>Data No.</td><td rowspan=1 colspan=1>PN-PUC(155.0mg/L)</td><td rowspan=1 colspan=1>PP-PUC(313.0mg/L)</td><td rowspan=1 colspan=1>Sample (L)</td><td rowspan=1 colspan=1>Sample (H)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>167.03</td><td rowspan=1 colspan=1>322.36</td><td rowspan=1 colspan=1>11.71</td><td rowspan=1 colspan=1>227.06</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>168.84</td><td rowspan=1 colspan=1>324.70</td><td rowspan=1 colspan=1>11.30</td><td rowspan=1 colspan=1>219.44</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>167.12</td><td rowspan=1 colspan=1>316.44</td><td rowspan=1 colspan=1>12.53</td><td rowspan=1 colspan=1>227.87</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>167.72</td><td rowspan=1 colspan=1>325.79</td><td rowspan=1 colspan=1>11.81</td><td rowspan=1 colspan=1>221.62</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>166.43</td><td rowspan=1 colspan=1>320.14</td><td rowspan=1 colspan=1>12.07</td><td rowspan=1 colspan=1>226.43</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>168.01</td><td rowspan=1 colspan=1>321.37</td><td rowspan=1 colspan=1>12.32</td><td rowspan=1 colspan=1>224.95</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>168.18</td><td rowspan=1 colspan=1>322.67</td><td rowspan=1 colspan=1>11.05</td><td rowspan=1 colspan=1>222.16</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>167.69</td><td rowspan=1 colspan=1>312.74</td><td rowspan=1 colspan=1>10.94</td><td rowspan=1 colspan=1>221.61</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>165.50</td><td rowspan=1 colspan=1>327.71</td><td rowspan=1 colspan=1>11.86</td><td rowspan=1 colspan=1>221.14</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>169.38</td><td rowspan=1 colspan=1>320.36</td><td rowspan=1 colspan=1>11.76</td><td rowspan=1 colspan=1>220.51</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>167.82</td><td rowspan=1 colspan=1>321.66</td><td rowspan=1 colspan=1>13.45</td><td rowspan=1 colspan=1>220.26</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>166.29</td><td rowspan=1 colspan=1>326.14</td><td rowspan=1 colspan=1>11.20</td><td rowspan=1 colspan=1>220.12</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>168.25</td><td rowspan=1 colspan=1>315.50</td><td rowspan=1 colspan=1>12.89</td><td rowspan=1 colspan=1>225.12</td></tr><tr><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>168.86</td><td rowspan=1 colspan=1>320.88</td><td rowspan=1 colspan=1>10.74</td><td rowspan=1 colspan=1>218.93</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>170.07</td><td rowspan=1 colspan=1>318.32</td><td rowspan=1 colspan=1>10.89</td><td rowspan=1 colspan=1>220.22</td></tr><tr><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>167.80</td><td rowspan=1 colspan=1>309.90</td><td rowspan=1 colspan=1>11.81</td><td rowspan=1 colspan=1>218.89</td></tr><tr><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>167.02</td><td rowspan=1 colspan=1>320.85</td><td rowspan=1 colspan=1>11.35</td><td rowspan=1 colspan=1>220.07</td></tr><tr><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>167.80</td><td rowspan=1 colspan=1>321.44</td><td rowspan=1 colspan=1>11.92</td><td rowspan=1 colspan=1>221.93</td></tr><tr><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>169.23</td><td rowspan=1 colspan=1>317.80</td><td rowspan=1 colspan=1>11.56</td><td rowspan=1 colspan=1>221.16</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>167.88</td><td rowspan=1 colspan=1>324.43</td><td rowspan=1 colspan=1>11.30</td><td rowspan=1 colspan=1>217.68</td></tr><tr><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>166.95</td><td rowspan=1 colspan=1>323.24</td><td rowspan=1 colspan=1>11.71</td><td rowspan=1 colspan=1>222.24</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Max.</td><td rowspan=1 colspan=1>170.07</td><td rowspan=1 colspan=1>327.71</td><td rowspan=1 colspan=1>13.45</td><td rowspan=1 colspan=1>227.87</td></tr><tr><td rowspan=1 colspan=1>Min.</td><td rowspan=1 colspan=1>165.50</td><td rowspan=1 colspan=1>309.90</td><td rowspan=1 colspan=1>10.74</td><td rowspan=1 colspan=1>217.68</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>4.57</td><td rowspan=1 colspan=1>17.81</td><td rowspan=1 colspan=1>2.71</td><td rowspan=1 colspan=1>10.19</td></tr><tr><td rowspan=1 colspan=1>Average</td><td rowspan=1 colspan=1>167.80</td><td rowspan=1 colspan=1>320.69</td><td rowspan=1 colspan=1>11.72</td><td rowspan=1 colspan=1>221.88</td></tr><tr><td rowspan=1 colspan=1>SD.</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>4.41</td><td rowspan=1 colspan=1>0.67</td><td rowspan=1 colspan=1>2.83</td></tr><tr><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>1.38</td><td rowspan=1 colspan=1>5.74</td><td rowspan=1 colspan=1>1.27</td></tr></table>

The between-day precision for the Sensitive application was determined by measuring one determination of two controls and two human CSF samples for twenty-one days on the Hitachi 917 analyzer.

<table><tr><td rowspan=1 colspan=5>Analyte:       IgGInstrument:   Hitachi 917Reagent:       IgGGC2 Lot E02Calibrator:    CfaS-PUC Lot 15575299 c227 mg/L. autodilutionResults:        Control Low  Control High  Human CSF</td></tr><tr><td rowspan=1 colspan=1>Day</td><td rowspan=1 colspan=1>PN-PUC(155.0mg/L)</td><td rowspan=1 colspan=1>PP-PUC(313.0mg/L)</td><td rowspan=1 colspan=1>Sample (L)</td><td rowspan=1 colspan=1>Sample (H)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>161.74</td><td rowspan=1 colspan=1>318.66</td><td rowspan=1 colspan=1>12.19</td><td rowspan=1 colspan=1>226.34</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>166.86</td><td rowspan=1 colspan=1>334.50</td><td rowspan=1 colspan=1>13.36</td><td rowspan=1 colspan=1>227.87</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>168.59</td><td rowspan=1 colspan=1>331.05</td><td rowspan=1 colspan=1>12.13</td><td rowspan=1 colspan=1>225.50</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>168.87</td><td rowspan=1 colspan=1>325.74</td><td rowspan=1 colspan=1>13.74</td><td rowspan=1 colspan=1>221.65</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>167.98</td><td rowspan=1 colspan=1>323.17</td><td rowspan=1 colspan=1>13.93</td><td rowspan=1 colspan=1>226.33</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>165.85</td><td rowspan=1 colspan=1>324.10</td><td rowspan=1 colspan=1>13.35</td><td rowspan=1 colspan=1>229.63</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>166.08</td><td rowspan=1 colspan=1>332.99</td><td rowspan=1 colspan=1>12.75</td><td rowspan=1 colspan=1>226.78</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>167.19</td><td rowspan=1 colspan=1>336.13</td><td rowspan=1 colspan=1>12.28</td><td rowspan=1 colspan=1>227.41</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>168.43</td><td rowspan=1 colspan=1>328.01</td><td rowspan=1 colspan=1>12.68</td><td rowspan=1 colspan=1>223.94</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>167.37</td><td rowspan=1 colspan=1>316.72</td><td rowspan=1 colspan=1>12.78</td><td rowspan=1 colspan=1>226.40</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>166.14</td><td rowspan=1 colspan=1>328.63</td><td rowspan=1 colspan=1>15.98</td><td rowspan=1 colspan=1>228.94</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>164.73</td><td rowspan=1 colspan=1>338.95</td><td rowspan=1 colspan=1>12.37</td><td rowspan=1 colspan=1>227.93</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>169.19</td><td rowspan=1 colspan=1>333.32</td><td rowspan=1 colspan=1>13.19</td><td rowspan=1 colspan=1>228.08</td></tr><tr><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>166.62</td><td rowspan=1 colspan=1>330.52</td><td rowspan=1 colspan=1>13.39</td><td rowspan=1 colspan=1>221.01</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>167.83</td><td rowspan=1 colspan=1>318.32</td><td rowspan=1 colspan=1>13.08</td><td rowspan=1 colspan=1>222.77</td></tr><tr><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>162.34</td><td rowspan=1 colspan=1>323.98</td><td rowspan=1 colspan=1>13.78</td><td rowspan=1 colspan=1>226.96</td></tr><tr><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>165.50</td><td rowspan=1 colspan=1>333.12</td><td rowspan=1 colspan=1>12.84</td><td rowspan=1 colspan=1>226.79</td></tr><tr><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>169.18</td><td rowspan=1 colspan=1>337.33</td><td rowspan=1 colspan=1>13.41</td><td rowspan=1 colspan=1>228.87</td></tr><tr><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>165.29</td><td rowspan=1 colspan=1>326.40</td><td rowspan=1 colspan=1>13.49</td><td rowspan=1 colspan=1>222.60</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>169.08</td><td rowspan=1 colspan=1>318.09</td><td rowspan=1 colspan=1>14.16</td><td rowspan=1 colspan=1>224.02</td></tr><tr><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>164.54</td><td rowspan=1 colspan=1>321.73</td><td rowspan=1 colspan=1>12.62</td><td rowspan=1 colspan=1>227.65</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Max.</td><td rowspan=1 colspan=1>169.19</td><td rowspan=1 colspan=1>338.95</td><td rowspan=1 colspan=1>15.98</td><td rowspan=1 colspan=1>229.63</td></tr><tr><td rowspan=1 colspan=1>Min.</td><td rowspan=1 colspan=1>161.74</td><td rowspan=1 colspan=1>316.72</td><td rowspan=1 colspan=1>12.13</td><td rowspan=1 colspan=1>221.01</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>7.45</td><td rowspan=1 colspan=1>22.23</td><td rowspan=1 colspan=1>3.85</td><td rowspan=1 colspan=1>8.62</td></tr><tr><td rowspan=1 colspan=1>Average</td><td rowspan=1 colspan=1>166.64</td><td rowspan=1 colspan=1>327.69</td><td rowspan=1 colspan=1>13.21</td><td rowspan=1 colspan=1>226.07</td></tr><tr><td rowspan=1 colspan=1>SD.</td><td rowspan=1 colspan=1>2.12</td><td rowspan=1 colspan=1>6.77</td><td rowspan=1 colspan=1>0.86</td><td rowspan=1 colspan=1>2.48</td></tr><tr><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>1.27</td><td rowspan=1 colspan=1>2.07</td><td rowspan=1 colspan=1>6.52</td><td rowspan=1 colspan=1>1.10</td></tr></table>

# b. Linearity/assay reportable range:

To determine the linear range, CSF samples are diluted with $\mathrm { N a C l }$ and measured on the Hitachi 917 using the Tina-Quant IgG Gen2 Sensitive Application (for CSF). Recovery is determined by comparison of the measured value to the theoretical value. The theoretical values were calculated according to the dilution factors. The acceptance criteria for linearity are based on recovery; and are as follows: for values below $1 5 \mathrm { m g / L }$ , recovery is within $\pm 3 \mathrm { m g / d L }$ . For values above $1 5 \mathrm { m g / L }$ , the acceptance criterion is recovery within $\pm 1 0 \%$ of the theoretical value.

The assay reportable range for the Tina-Quant IgG Gen2 Sensitive Application (for CSF) is $2 { - } 2 0 0 \ \mathrm { m g / L }$ . The linearity data support a linear range from 0 to $3 3 0 . 4 \mathrm { m g / L }$ .

# 1.) Linearity Low Range

<table><tr><td colspan="7">Measured Values and Recovery</td></tr><tr><td>Nr</td><td>Sample-Id</td><td>Diluton low</td><td>Dilution High</td><td>Measured Value</td><td>Theoretical Value</td><td>Recovery [%]</td></tr><tr><td>0</td><td>LIN1</td><td>10.00</td><td>0.00</td><td>1.635</td><td>0.000</td><td></td></tr><tr><td></td><td>LIN2</td><td>9.00</td><td>1.00</td><td>1.915</td><td>2.980</td><td>64.262</td></tr><tr><td></td><td>LIN3</td><td>8.00</td><td>2.00</td><td>3.195</td><td>5.960</td><td>53.607</td></tr><tr><td></td><td>LIN4</td><td>7.00</td><td>3.00</td><td>6.230</td><td>8.940</td><td>69.687</td></tr><tr><td></td><td>LINS .</td><td>6.00</td><td>4.00</td><td>9.615</td><td>11.920</td><td>80.663</td></tr><tr><td>-NMA</td><td>LIN6 *</td><td>5.00</td><td>5.00</td><td>13.385</td><td>14.900</td><td>89.832</td></tr><tr><td></td><td>LIN7 -</td><td>4.00</td><td>6.00</td><td>17.565</td><td>17.880</td><td>98.238</td></tr><tr><td></td><td>LIN8</td><td>3.00</td><td>7.00</td><td>20.860</td><td>20.860</td><td>100.000</td></tr><tr><td>0-∞0</td><td>LIN9 *</td><td>2.00</td><td>8.00</td><td>24.500</td><td>23.840</td><td>102.768</td></tr><tr><td></td><td>LIN10</td><td>1.00</td><td>9.00</td><td>28.175</td><td>26.820</td><td>105.052</td></tr><tr><td>10</td><td>LIN11</td><td>0.00</td><td>10.00</td><td>32.045</td><td>29.800</td><td>107.534</td></tr></table>

")Dilutions used for caloulation of regression line

![](images/353c2daada6c67ce685c47dd60cc5bfab9a4aedd3edbaaa2cbe6e3cf1f8d5d96.jpg)

In addition, linearity is also determined for the extended measuring range with rerun which is $ { 2 \mathrm { - } 1 0 0 0 \mathrm { m g / L } }$ . The extended measuring range is calculated based on the ability of the instrument to perform rerun pipetting. Results outside the measuring (reportable) range are reported to the user with a flag warning that the value is outside the instrument's technical limit. Users can select an automatic rerun with dilution, or manually dilute the sample with $0 . 9 \%$ NaCl and rerun, multiplying the results by an appropriate factor. This function is the same as the already cleared serum and plasma applications.

<table><tr><td colspan="7">Measured Values and Recovery</td></tr><tr><td>Nr</td><td>Sample-Id</td><td>Dilution low</td><td>Dilution High</td><td>Measured Value</td><td>Theoretical Value</td><td>Recovery [%]</td></tr><tr><td>0</td><td>LIN1</td><td>10.00</td><td>0.00</td><td>1.635</td><td>0.000</td><td>-</td></tr><tr><td></td><td>LIN2</td><td>9.00</td><td>1.00</td><td>1.915</td><td>2.980</td><td>64.262</td></tr><tr><td></td><td>LIN3</td><td>8.00</td><td>2.00</td><td>3.195</td><td>5.960</td><td>53.607</td></tr><tr><td></td><td>LIN4</td><td>7.00</td><td>3.00</td><td>6.230</td><td>8.940</td><td>69.687</td></tr><tr><td>-NOV</td><td>LINS .</td><td>6.00</td><td>4.00</td><td>9.615</td><td>11.920</td><td>80.663</td></tr><tr><td></td><td>LIN6 .</td><td>5.00</td><td>5.00</td><td>13.385</td><td>14.900</td><td>89.832</td></tr><tr><td></td><td>LIN7 .</td><td>4.00</td><td>6.00</td><td>17.565</td><td>17.880</td><td>98.238</td></tr><tr><td></td><td>LIN8 :</td><td>3.00</td><td>7.00</td><td>20.860</td><td>20.860</td><td>100.000</td></tr><tr><td>0-∞0</td><td>LIN9 .</td><td>2.00</td><td>8.00</td><td>24.500</td><td>23.840</td><td>102.768</td></tr><tr><td></td><td>LIN10 .</td><td>1.00</td><td>9.00</td><td>28.175</td><td>26.820</td><td>105.052</td></tr><tr><td>10</td><td>LIN11 .</td><td>0.00</td><td>10.00</td><td>32.045</td><td>29.800</td><td>107.534</td></tr></table>

") Dilutions used for caloulation of regression line

![](images/f31911bfc77ee7ac744547708a92a4f15fb64e9269462b26debab499158ecd71.jpg)  
Passing/Bablok - Regression: y = 0 + 2.98 \*x

c. Traceability, Stability, Expected values (controls, calibrators, or methods): The method has been standardized against CRM 470 (RPPHS, Reference Preparation for Proteins in Human Serum).

d. Detection limit:

Twenty-one replicates of the zero calibrator $( 0 . 9 \% \mathrm { N a C l } )$ ) were tested in each of three independent runs on a Hitachi 917 analyzer using the Tina-Quant IgG

Gen2 Sensitive application (for CSF). The detection limit represents the lowest measurable level that can be distinguished from zero. It is calculated as the mean plus three standard deviations. The lower detection limit is $2 \mathrm { m g / L }$ .

e. Analytical specificity:

i.) Endogenous interferences: The effect of hemoglobin and bilirubin interference on the quantitation of IgG in CSF via the Tina-Quant IgG Gen 2 Sensitive Application was determined on the Hitachi 917 analyzer using two native human CSF samples (with low and midrange IgG concentrations) spiked with varying concentrations of interferent. In separate experiments: hemoglobin, conjugated and unconjugated bilirubin were tested). The resulting sample series were tested and recovery was calculated by comparing the measured $\mathrm { I g G }$ concentration to the expected $\mathrm { I g G }$ concentration (measured $\mathrm { I g G }$ concentration with no interferent present). Significant interference was considered present if the %recovery exceeded $\pm 1 0 \%$ of the expected value. The following results are obtained: Icterus: No significant interference up to an I index of 60(approximate conjugated and unconjugated bilirubin concentration: $6 0 \mathrm { m g / d L }$ or 1026 $\mu \mathrm { m o l / L } )$ .

Hemolysis: No significant interference up to an $\mathrm { H }$ index of 800 (approximate hemoglobin concentration: $8 0 0 \mathrm { m g / d L }$ or $4 9 7 \mu \mathrm { m o l / L }$ ). There is no cross-reaction between IgG and IgA or $\mathrm { I g M }$ for serum and plasma. Cross-reactivity studies were not performed for CSF.

Carryover: The Tina-Quant IgG Gen 2 Sensitive Application (for CSF) shows some carryover interference from IgG present in previously measured serum samples. Carryover can be avoided by performing a wash with NaOH prior to measurement of IgG in CSF. To characterize this carryover effect, $1 5 \mu \mathrm { L }$ of undiluted serum was tested on a Hitachi 917 analyzer using the Fe (iron) test reagent, immediately prior to 5 determinations of $\mathrm { I g G }$ in CSF using the Tina-Quant IgG Gen 2 Sensitive Application. The CSF samples contained a low concentration of CSF. The experiment was repeated; employing a 1N NaOH wash between the serum iron and IgG CSF determinations. A significant carry-over effect was considered present if the calculated values were greater than $\pm 1 5 \%$ of the known value. The data show that the wash eliminates the carry-over effect.

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device: Fifty four (54) human CSF samples from multiple donors with concentrations between 6.17 and $6 5 . 5 \mathrm { m g / L }$ were used in a method comparison study between Tina-Quant $^ \mathrm { \textregistered }$ IgG Gen.2 Sensitive Application and the predicate device, Dade-Behring N-Antisera to Human IgG on the BNII (X). The expected range of values is $1 0 - 3 0 \mathrm { m g / L }$ . Samples were frozen at the site of collection and sent to Roche GmbH for testing. Comparison of the IgG values obtained with Tina-Quant $^ \mathrm { \textregistered }$ IgG Gen.2 Sensitive Application (Y) to the

values obtained with the predicate device: Dade-Behring N-Antisera to Human $\mathrm { I g G }$ on the BNII (X) are summarized below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>PassIng/Bablok</td><td rowspan=1 colspan=1>Least Squares</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>54</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>6.17 -65.5 mg/L</td><td rowspan=1 colspan=1>6.17 65.5 mg/L</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>1.066</td><td rowspan=1 colspan=1>1.04</td></tr><tr><td rowspan=1 colspan=1>Y intercept</td><td rowspan=1 colspan=1>-4.451</td><td rowspan=1 colspan=1>-3.903</td></tr><tr><td rowspan=1 colspan=1>correlation</td><td rowspan=1 colspan=1>Tau = 0.939</td><td rowspan=1 colspan=1>r = 0.988</td></tr><tr><td rowspan=1 colspan=1>deviation</td><td rowspan=1 colspan=1>SD (md95)= 2.289</td><td rowspan=1 colspan=1>Sy.x = 1.44</td></tr></table>

Graph of Method Comparison between Tina-Quant IgG Gen.2 Sensitive Application (y) and Dade-Behring N Antisera to Human IgG on the BNII (x)

![](images/be6a238c73e4cef5bfc90eaeb5303012cfdd282512c44268777ba7ecedfb941d.jpg)

b. Matrix comparison: Not applicable

3. Clinical studies: a. Clinical Sensitivity: Not applicable b. Clinical specificity: Not applicable c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Reference values: $1 0 { - } 3 0 \ \mathrm { m g / L }$ (66.7–200 nmol/L) were from literature citation.

[Reference: Reiber H, Thompson EJ, Grimsley G et al. Quality Assurance for Cerebrospinal Fluid Protein Analysis: International Consensus by an Internet-based Group Discussion. Clin Chem Lab Med 2003; 41: 331-337.]

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.